| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1973-10-26 |
| Identifiers | MRN HR-ML035-SYN; SSN (made up) 000-35-4692 |
| Document date | 2026-10-05 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Jackson, 52, comes for her yearly preventive visit six weeks after the review at which the repeat FDG-PET showed no active heart inflammation. Prednisone was reduced to 7.5 mg two weeks ago as planned; she takes methotrexate 20 mg weekly with folic acid, metoprolol, alendronate and vitamin D. She has more energy, climbs two flights of stairs without stopping, and has sung two concerts a week since the spring, with a longer tour planned for later in the autumn. The hoarseness in June settled within ten days. Her defibrillator has given no shocks, and the remote check last month was normal. She sleeps well now that the prednisone dose is lower. Her PHQ-9 today is 3. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 52 |
| Active conditions | Pulmonary and cardiac sarcoidosis in remission on treatment; dual-chamber defibrillator; long-term glucocorticoids |
| Medicines | Prednisone 7.5 mg daily; methotrexate 20 mg weekly with folic acid 1 mg daily; metoprolol succinate 25 mg; alendronate 70 mg weekly; cholecalciferol 1000 units daily |
| Mood | PHQ-9 3 |
Health risk assessment. Completed on paper in the waiting room and reviewed with her by Dr. Fontenot. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and much better than in the winter |
| Psychosocial | Faith and her church community are her strength; touring is tiring but is her purpose; worried about money while concerts were cancelled |
| Tobacco | Never smoked |
| Alcohol and drugs | No alcohol (she avoids it on methotrexate) and no drugs |
| Physical activity | Walks 30 minutes most days at home; less on tour |
| Nutrition | Home cooking at home; irregular meals on tour; has cut down on sweet drinks since her A1c rose; no calcium tablets, dairy twice a day |
| Sleep | Seven hours since the prednisone was lowered |
| Safety at home | Feels safe; no one hurts, threatens or controls her |
| Road safety | Wears a seat belt; driven on tour |
| Falls | No falls |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; no fever, night sweats or weight change |
| Eyes | Negative | No redness, pain, blurred vision or floaters |
| Ears, nose, mouth, and throat | Negative | Voice back to normal; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations, fainting or device shocks |
| Respiratory | Negative | Breathless only on hills; no cough |
| Gastrointestinal | Negative | No heartburn with alendronate; no change in bowel habit or blood |
| Genitourinary | Negative | No urinary symptoms or vaginal bleeding |
| Breast | Negative | No lump, skin change or nipple discharge |
| Musculoskeletal | Negative | No bone pain or joint swelling |
| Integumentary | Negative | No rash, nodules or skin plaques; easy bruising less now |
| Neurological | Negative | No numbness, weakness or headache |
| Endocrine | Negative | No thirst or frequent urination |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning | 40 mg each morning | Oral route | 2026-03-09 to 2026-05-11 | completed | S |
| Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks | 30 mg each morning for four weeks | Oral route | 2026-05-11 to 2026-06-08 | completed | S |
| Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks | 20 mg each morning for four weeks | Oral route | 2026-06-08 to 2026-07-06 | completed | S |
| Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks | 15 mg each morning for four weeks | Oral route | 2026-07-06 to 2026-08-03 | completed | S |
| Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning | 10 mg each morning | Oral route | 2026-08-03 to 2026-09-21 | completed | S |
| Prednisone 5 mg oral tablet, one and a half tablets (7.5 mg) by mouth each morning | 7.5 mg each morning | Oral route | 2026-09-21 | active | S |
| Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays | 15 mg once weekly | Oral route | 2026-03-09 to 2026-05-11 | completed | S |
| Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays | 20 mg once weekly | Oral route | 2026-05-11 | active | S |
| Folic acid 1 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food | 1500 mg once daily with food | Oral route | 2026-03-09 to 2026-07-06 | completed | S |
| Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes | One tablet once weekly | Oral route | 2026-03-16 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 2026-05-11 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-05 | Body height | 170 | cm | S |
| 2026-10-05 | Body weight | 92.2 | kg | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 31.9 | kg/m2 | S |
| 2026-10-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-10-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-10-05 | Heart rate | 66 | /min | S |
| 2026-10-05 | Respiratory rate | 16 | /min | S |
| 2026-10-05 | Body temperature | 36.7 | Cel | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-05 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=200 mg/dL | High | S |
| 2026-10-05 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-10-05 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 126 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-10-05 | Triglyceride [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-10-05; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 92.2 kg, BMI 31.9; blood pressure 128/80 (average of two) |
| Eyes | No redness; pupils equal and reactive |
| Head, eyes, ears, nose, and throat | No thrush; voice clear |
| Neck | No lymph nodes; thyroid normal |
| Breasts | Examined with her agreement and a chaperone: no mass, skin change or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; defibrillator pocket healed; no ankle swelling |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Old lower midline scar; soft; no liver or spleen enlargement |
| Pelvic | Speculum examination with her agreement and a chaperone: vaginal cuff healed, no cervix present |
| Skin | No rash, nodules or plaques; no suspicious lesions |
| Musculoskeletal | Height 170 cm, unchanged; no spinal tenderness |
| Psychiatric | Warm, lively, engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | resolved | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
| Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolved | resolved | confirmed | J04.0 | S — Synthetic acute infection; not a historical claim. |
| Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | D86.85 | S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R. |
| Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | Z79.52 | S — Synthetic treatment status. |
| Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring | active | confirmed | Z95.810 | S — Synthetic device status after the synthetic implant. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 128/80 mmHg, lower than on high-dose prednisone |
| Depression screening | Completed today | PHQ-9 score 3; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | No alcohol |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Breast cancer screening | Ordered | Mammogram every two years from 40; last one three years ago; ordered today |
| Colorectal cancer screening | Up to date | Colonoscopy six years ago normal; next due in four years |
| Cervical cancer screening | Not indicated | No cervix on examination today after hysterectomy, and no history of cervical precancer |
| Diabetes screening | Completed today | A1c 6.2% in August: prediabetes; diabetes prevention program offered |
| Cholesterol screening and statin decision | Completed today | Total cholesterol 204, HDL 54, LDL 126 mg/dL; ten-year risk about 4 percent; no statin now |
| Osteoporosis screening and glucocorticoid bone protection | Up to date | Bone density in March, T-score -1.6; on alendronate; repeat in two years |
| HIV and hepatitis C screening | Up to date | Both negative at the consultation in February |
| Influenza vaccine | Completed today | Inactivated vaccine given |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine given |
| Pneumococcal vaccine | Up to date | PCV20 in March, before immunosuppression |
| Recombinant zoster vaccine | Up to date | Two doses, March and August |
| Hepatitis B vaccine | Up to date | Two-dose adjuvanted series completed in May |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap six years ago |
| Live vaccines (MMR, varicella) | Not indicated | Avoided on prednisone and methotrexate |
| Eye examination | Up to date | Ophthalmology in March normal (no uveitis); yearly while on glucocorticoids and with sarcoidosis |
| Dental examination | Due | Before the autumn tour; alendronate noted for the dentist |
Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula [S]
Guideline basis: Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022)
Follow-up: Mammogram within the month. Methotrexate blood tests next month. Pulmonology and cardiology as planned. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 30 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here, and completed a health care power of attorney. She said that her faith guides her, that she wants every treatment that gives her a good chance to live and to sing, and that if she became so ill that she could not recover to know and pray with the people around her, she would want comfort care and her church's prayers rather than machines. The defibrillator was explained: it can be switched off painlessly by the device team if she ever chooses comfort care at the end of life, and she asked that this be discussed with her agent then. To be revisited at each change in her health and at least yearly. [S]